Shilpa Gupta, MD, discusses the progress over the last few years in bladder cancer.
Shilpa Gupta, MD, genitourinary oncologist at the University of Minnesota, discusses the progress made with immunotherapy in bladder cancer over the last few years.
There has been many advances in terms of immunotherapy in this patient population, and many trials are combining chemotherapy with these agents in the hopes of improving overall survival and gaining more durable responses, says Gupta. Later this year, we will learn more about these data as they read out.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More